Skip to main content
Log in

Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD)

  • Review
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often persists in adulthood. Methylphenidate (MPH) is one of the most effective medications to treat ADHD, but also few adult patients show no sufficient response to this drug. In this paper, we give an overview regarding genetic, neuroimaging, clinical and other studies which have tried to reveal the reasons for non-response in adults with ADHD, based on a systematic literature search. Although MPH is a well-established treatment for adults with ADHD, research regarding the prediction of treatment outcome is still limited and has resulted in inconsistent findings. No reliable neurobiological markers of treatment response have been identified so far. Some findings from clinical studies suggest that comorbidity with substance use disorders and personality disorders has an impact on treatment course and outcome. As MPH is widely used in the treatment of adults with ADHD, much more work is needed regarding positive and negative predictors of long-term treatment outcome in order to optimize the pharmacological treatment of adult ADHD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 20:386–392

    Article  PubMed  Google Scholar 

  2. Fayyad J, De Graf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lépine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409

    Article  PubMed  CAS  Google Scholar 

  3. Barkley RA, Fischer M, Smallish L, Fletcher K (2006) Young adult outcome of hyperactive children; adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:92–202

    Article  Google Scholar 

  4. Stein MA (2004) Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care 10:S89–S98

    PubMed  Google Scholar 

  5. Retz W, Retz-Junginger P, Thome J, Rösler M (2011) Pharmacological treatment of adult ADHD in Europe. World J Biol Psychiatry 12(Suppl 1):89–94

    Article  PubMed  Google Scholar 

  6. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101

    Article  PubMed  CAS  Google Scholar 

  7. Rösler M, Fischer R, Ammer R, Ose C, Retz W (2009) A randomised, placebo-controlled, 24-week, study of low dose extended-release methylphenidate in adults with attentiondeficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129

    Article  PubMed  Google Scholar 

  8. Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R (2010) Twenty-for-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 11:709–718

    Article  PubMed  Google Scholar 

  9. Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG (2011) Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord 15:295–304

    Article  PubMed  Google Scholar 

  10. Spencer TJ, Adler LA, Weisler RH, Youcha SH (2008) Triplebead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 69:1437–1448

    Article  PubMed  CAS  Google Scholar 

  11. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA (2011) A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 15:35–45

    Article  Google Scholar 

  12. Huss M, Ginsberg Y, Tvedten T, Arngrim T, Philipsen A, Carter K, Chen CW, Kumar V (2014) Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther 31:44–65

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R (2012) Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 13:48–59

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B (2013) Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attentiondeficit/hyperactivity disorder treated with OROS methylphenidate. World J Biol Psychiatry 14:282–290

    Article  PubMed  Google Scholar 

  15. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 24:24–39

    Article  PubMed  CAS  Google Scholar 

  16. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744

    Article  PubMed  CAS  Google Scholar 

  17. Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147

    Article  PubMed  Google Scholar 

  18. Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763

    Article  PubMed  Google Scholar 

  19. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169

    Article  PubMed  CAS  Google Scholar 

  20. Ebert D, Krause J, Roth-Sackenheim C, the DGPPN Expert Committee (2003) ADHD in adulthood—guidelines based on expert consensus with DGPPN support. Nervenarzt 74:939–946

    PubMed  CAS  Google Scholar 

  21. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10–41

    Article  PubMed  CAS  Google Scholar 

  22. National Institute for Health and Clinical Excellence (2008) Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. www.NICE.org.uk

  23. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (2012) Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry 51:1003–1019

    Article  PubMed  Google Scholar 

  24. Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA, Mick E, Grevet EH, Johansson S, Haavik J, Lesch KP, Cormand B, Reif A; International Multicentre persistent ADHD Collaboration (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17:960–987

    Article  Google Scholar 

  25. Zhou K, Dempfle A, Arcos-Burgos M, Bakker SC, Banaschewski T, Biederman J, Buitelaar J, Castellanos FX, Doyle A, Ebstein RP, Ekholm J, Forabosco P, Franke B, Freitag C, Friedel S, Gill M, Hebebrand J, Hinney A, Jacob C, Lesch KP, Loo SK, Lopera F, McCracken JT, McGough JJ, Meyer J, Mick E, Miranda A, Muenke M, Mulas F, Nelson SF, Nguyen TT, Oades RD, Ogdie MN, Palacio JD, Pineda D, Reif A, Renner TJ, Roeyers H, Romanos M, Rothenberger A, Schäfer H, Sergeant J, Sinke RJ, Smalley SL, Sonuga-Barke E, Steinhausen HC, van der Meulen E, Walitza S, Warnke A, Lewis CM, Faraone SV, Asherson P (2008) Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1392–1398

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Retz W, Thome J, Blocher D, Baader M, Rösler M (2002) Association of attention deficit hyperactivity disorder-related psychopathology and personality traits with the serotonin transporter promoter region polymorphism. Neurosci Lett 319:133–136

    Article  PubMed  CAS  Google Scholar 

  27. Retz W, Rösler M, Kissling C, Wiemann S, Hünnerkopf R, Coogan A, Thome J, Freitag C (2008) Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm 115:323–329

    Article  PubMed  CAS  Google Scholar 

  28. de Azeredo LA, Rovaris DL, Mota NR, Polina ER, Marques FZ, Contini V, Vitola ES, Belmonte-de-Abreu P, Rohde LA, Grevet EH, Bau CH (2014) Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults. Eur Arch Psychiatry Clin Neurosci 264:401–408

    Article  PubMed  Google Scholar 

  29. Reif A, Jacob CP, Rujescu D, Herterich S, Lang S, Gutknecht L, Bähne CG, Strobel A, Freitag CM, Giegling I, Romanos M, Hartmann A, Rösler M, Renner TJ, Fallgatter AJ, Retz W, Ehlis AC, Lesch KP (2009) Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans. Arch Gen Psychiatry 66:41–50

    Article  PubMed  CAS  Google Scholar 

  30. Weber H, Scholz CJ, Jacob CP, Heupel J, Kittel-Schneider S, Erhardt A, Hempel S, Schmidt B, Kiel T, Gessner A, Lesch KP, Reif A (2014) SPOCK3, a risk gene for adult ADHD and personality disorders. Eur Arch Psychiatry Clin Neurosci 264:409–421

    Article  PubMed  Google Scholar 

  31. Li Z, Chang SH, Zhang LY, Gao L, Wang J (2014) Molecular genetic studies of ADHD and its candidate genes: a review. Psychiatr Res 219:10–24

    Article  CAS  Google Scholar 

  32. Lee HY, Song GG (2014) Genome-wide pathway analysis in attention-deficit/hyperactivity disorder. Neurol Sci 35:1189–1196

    Article  PubMed  Google Scholar 

  33. Retz W, Freitag CM, Retz-Junginger P, Wenzler D, Schneider M, Kissling C, Thome J, Rösler M (2008) A functional serotonin transporter promoter gene polymorphism increases ADHD symptoms in delinquents: interaction with adverse childhood environment. Psychiatr Res 158:123–131

    Article  CAS  Google Scholar 

  34. Getahun D, Rhoads GG, Demissie K, Lu SE, Quinn VP, Fassett MJ, Wing DA, Jacobsen SJ (2013) In utero exposure to ischemic-hypoxic conditions and attention-deficit/hyperactivity disorder. Pediatrics 131:e53–e61

    Article  PubMed  Google Scholar 

  35. Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Contini V, Kieling C, Hutz MH, Rohde LA (2014) ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B Neuropsychiatr Genet 165B:263–282

    Article  PubMed  Google Scholar 

  36. Froehlich TE, McGough JJ, Stein MA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99–117

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Polanczyk G, Bigarella MP, Hutz MH, Rohde LA (2010) Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des 16:2462–2473

    Article  PubMed  CAS  Google Scholar 

  38. Contini V, Victor MM, Bertuzzi GP, Salgado CA, Picon FA, Grevet EH, Rohde LA, Belmonte-de-Abreu P, Bau CH (2012) No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. J Clin Psychopharmacol 32:820–823

    Article  PubMed  CAS  Google Scholar 

  39. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV (2008) Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1412–1418

    Article  PubMed  CAS  Google Scholar 

  40. Evans KC, Dougherty DD, Pollack MH, Rauch SL (2006) Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry 18:33–42

    Article  PubMed  Google Scholar 

  41. Shaw P, Lerch J, Greenstein D, Sharp W, Clasen L, Evans A, Giedd J, Castellanos FX, Rapoport J (2006) Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attentiondeficit/hyperactivity disorder. Arch Gen Psychiatry 63:540–549

    Article  PubMed  Google Scholar 

  42. Semrud-Clikeman M, Filipek PA, Biederman J, Steingard R, Kennedy D, Renshaw P, Bekken K (1994) Attention-deficit hyperactivity disorder: magnetic resonance imaging morphometric analysis of the corpus callosum. J Am Acad Child Adolesc Psychiatry 33:875–881

    Article  PubMed  CAS  Google Scholar 

  43. Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J (1997) Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 48:589–601

    Article  PubMed  CAS  Google Scholar 

  44. Mackie S, Shaw P, Lenroot R, Pierson R, Greenstein DK, Nugent TF 3rd, Sharp WS, Giedd JN, Rapoport JL (2007) Cerebellar development and clinical outcome in attention deficit hyperactivity disorder. Am J Psychiatry 164:647–655

    Article  PubMed  Google Scholar 

  45. Skokauskas N, Hitoshi K, Shuji H, Frodl T (2013) Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD. Eur J Paediatr Neurol 17:545–551

    Article  Google Scholar 

  46. Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH (2005) Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 255:428–431

    Article  PubMed  Google Scholar 

  47. la Fougère C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S (2006) Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 27:733–737

    Article  PubMed  Google Scholar 

  48. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159:309–312

    Article  PubMed  Google Scholar 

  49. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD (2003) Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30:306–311

    Article  PubMed  CAS  Google Scholar 

  50. Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S (2001) Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev Med Child Neurol 43:755–760

    Article  PubMed  CAS  Google Scholar 

  51. Cho SC, Hwang JW, Kim BN, Lee HY, Kim HW, Lee JS, Shin MS, Lee DS (2007) The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders. J Psychiatr Res 41:459–465

    Article  PubMed  Google Scholar 

  52. Schweitzer JB, Lee DO, Hanford RB, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD (2003) A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology 28:967–973

    PubMed  CAS  Google Scholar 

  53. Sabate E (2003) Adherence to long-term therapies: evidence for action. World Health Organisation, Geneva. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf

  54. Hodgkins P, Sasane R, Christensen L, Harley C, Liu F (2001) Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin 27:53–62

    Article  Google Scholar 

  55. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S (2010) Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 26:977–989

    Article  PubMed  CAS  Google Scholar 

  56. Adler LD, Nierenberg AA (2010) Review of medication adherence in children and adults with ADHD. Postgrad Med 122:184–191

    Article  PubMed  Google Scholar 

  57. Caisley H, Mueller U (2012) Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. Eur Psychiatry 27:343–349

    Article  PubMed  CAS  Google Scholar 

  58. Kooij JJ, Rösler M, Philipsen A, Wächter S, Dejonckheere J, van der Kolk A, van Agthoven M, Schäuble B (2013) Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. BMC Psychiatry 13:36

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  59. Sobanski E, Retz W, Fischer R, Ose C, Alm B, Hennig O, Rösler M (2014) Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate. Eur Psychiatry 29:324–330

    Article  PubMed  CAS  Google Scholar 

  60. Miller TW, Nigg JT, Faraone SW (2007) Axis I and II comorbidity in adults with ADHD. J Abnorm Psychol 116:519–528

    Article  PubMed  Google Scholar 

  61. Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, Philipsen A, Rietschel M (2007) Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 257:371–377

    Article  PubMed  Google Scholar 

  62. Ollendick TH, Jarrett MA, Grills-Taquechel AE, Hovey LD, Wolff JC (2008) Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/conduct disorders. Clin Psychol Rev 28:1447–1471

    Article  PubMed  Google Scholar 

  63. Wilens TE (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283–301

    Article  PubMed  Google Scholar 

  64. Cunill R, Castells X, Tobias A, Capellà D (2014) Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. doi:10.1177/0269881114544777

  65. Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE (2010) Personality disorders in ADHD Part 2: the effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Ann Clin Psychiatry 22:94–102

    PubMed  Google Scholar 

  66. Torgersen T, Gjervan B, Nordahl HM, Rasmussen K (2012) Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study. J Clin Psychopharmacol 32:645–652

    Article  PubMed  Google Scholar 

  67. Ginsberg Y, Lindefors N (2012) Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry 200:68–73

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

WR is a member of the advisory board of Medice and has been invited speaker for Novartis. PRJ has no conflicts of interests to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wolfgang Retz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Retz, W., Retz-Junginger, P. Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 264 (Suppl 1), 35–43 (2014). https://doi.org/10.1007/s00406-014-0542-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0542-4

Keywords

Navigation